Role of sialic acid and alkaline DNase in breast cancer

International Journal of Biological Markers

Volumn 12, Issue 2, 1997, Pages 61-67

  Raval, G N ^a   Parekh, L J ^b   Patel, M M ^a   Patel, P S ^a   Rawal, R M ^a   Balar, D B ^a   Patel, D D ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Alkaline DNase; Breast cancer; Enzymes; Glycoproteins; Sialic acid; Tumor markers

Indexed keywords

DEOXYRIBONUCLEASE; SIALIC ACID; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; SPECTROPHOTOMETRY; STATISTICAL ANALYSIS;

EID: 0030821693     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200204     Document Type: Article

References (22)

1. Suresh MR, Classification of tumor markers. Anticancer Res 1996; 16: 2273-7.
2. Sell S. Detection of cancer by tumor markers in the blood: a view to the future. Critical Reviews in Oncogenesis 1993; 4: 419-33.
3. Lopez Saez JJB, Senra-Varela A. Evaluation of lipid-bound sialic acid (LSA) as a tumor marker. Int J Biol Markers 1995; 10: 174-9.
4. Schutter EMJ, Visser JJ, Mensdorff-Pouilly S, van Dijk W, Hilgers J, Kenemans P. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy (Review). Tumor Biol 1992; 13: 121-32.
5. Plucinsky MC, Riley WM, Prorok JJ, Alhadeff JA. Total and lipid-associated serum sialic acid levels in cancer patients with different primary sites and differing degrees of metastatic involvement. Cancer 1986; 58: 2680-5.
6. Stringou E, Chondros K, Kouvaris J, Kakari S, Papavassiliou K. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients under-going radiotherapy. Anticancer Res 1992; 12: 251-6.
7. Patel PS, Baxi BR, Adhvaryu SG, Balar DB. Evaluation of serum sialic acid, heat-stable alkaline phosphatase and fucose as markers of breast carcinoma. Anticancer Res 1990; 10: 1071-4.
8. Patel PS, Baxi BR, Adhvaryu SG, Balar DB. Individual and combined usefulness of lipid associated sialic acid, mucoid proteins and hexoses as tumor markers in breast carcinoma. Cancer Letters 1990; 51: 203-8.
9. Love JD, Hewitt RR. The relationship between human serum and human pancreatic DNase 1. J Biol Chem 1979; 254: 12588-94.
10. Taper HS, Deckers CO, Deckers-Passau LO. Increase in nuclease activity as a possible means for detecting tumor cell sensitivity to anticancer agents. Cancer 1981; 47: 523-9.
11. Taper H, Lans M, Economidou-Karaoglou A, de Gerlache J, Roberfroid M, Variations in serum alkaline DNase activity: a possible clinical test for therapeutic prognosis of human tumors. Anticancer Res 1986; 6: 949-56.
12. Economidou-Karaoglou A, Opsomer M, Petit G, Lans M, Taper HS, Roberfroid MB. Characteristic variations of serum alkaline DNase activity in relation to response to therapy and tumor prognosis in human lung cancer. Eur J Cancer Clin Oncol 1988; 24: 1337-43.
13. Harris JR, Morrow M, Bonadonna G, Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. Philadelphia: Lippincott, 1993; 1264-332.
14. Loiselle JM, Carrier R. Deoxyribonuclease serique chez les cancereux. Rev Can Biol 1963; 22: 341-6.
15. Feinstein AR. Clinical epidemiology, in the architecture of clinical research. Philadelphia: WB Saunders, 1985; 601-9.
16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982: 143: 29-36.
17. Kobayashi T, Kawakubo T. Prospective investigation of tumor markers and risk assessment in early cancer screening. Cancer 1994; 73: 1946-53.
18. Yue K, Bian M, Zhu D, Liu W, Siu S. Serum lipid associated sialic acid (LSA) in diagnosis and monitoring ovarian cancer. Chung Kuo I Hsueh Ko Hseuh Yuan Hsueh Pao. 1995; 17: 128-32.
19. Economidou-Karaoglou A, Lans M, Taper HS, Michaux JL, Roberfroid M. Variations of serum alkaline DNase activity: a new means for therapeutic monitoring of malignant lymphomas. Cancer 1988; 61: 1838-43.
20. Xing R, Chen R, Wang Z, Zhang Y. Serum sialic acid levels in patients with oral and maxillofacial malignancy. J Oral Maxillofac Surg 1991; 49: 643-7.
21. Kvinnsland S. Serum tumour markers in clinical practice: Some general aspects. Scand J Clin Lab Invest 1991; 206: 6-11.
22. Jotti GS, Bombardieri E. Circulating tumor markers in breast cancer (review). Anticancer Res 1990; 10: 253-8.